Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

Mercè Padró, Raymond J. Louie, Brian V. Lananna, Adam Krieg, Luika A. Timmerman, Denise A. Chan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: About 75-80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Methods: Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. Results: We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. Conclusions: These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.

Original languageEnglish (US)
Article number203
JournalBMC Cancer
Volume17
Issue number1
DOIs
StatePublished - Mar 20 2017
Externally publishedYes

Fingerprint

Estrogen Receptor alpha
Genome
Breast Neoplasms
Hypoxia-Inducible Factor 1
Cell Line
Neoplasms
Oxygen
Incubators
Proteasome Endopeptidase Complex
Therapeutics
Biological Assay

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Drug resistance
  • Endocrine therapy
  • Endocrine therapy resistance
  • Estrogen receptor
  • HIF
  • HIF-1 alpha
  • HIF-1α
  • Hypoxia
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Padró, M., Louie, R. J., Lananna, B. V., Krieg, A., Timmerman, L. A., & Chan, D. A. (2017). Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells. BMC Cancer, 17(1), [203]. https://doi.org/10.1186/s12885-017-3140-9

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells. / Padró, Mercè; Louie, Raymond J.; Lananna, Brian V.; Krieg, Adam; Timmerman, Luika A.; Chan, Denise A.

In: BMC Cancer, Vol. 17, No. 1, 203, 20.03.2017.

Research output: Contribution to journalArticle

Padró, Mercè ; Louie, Raymond J. ; Lananna, Brian V. ; Krieg, Adam ; Timmerman, Luika A. ; Chan, Denise A. / Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells. In: BMC Cancer. 2017 ; Vol. 17, No. 1.
@article{d6f47284995e4300a9290c542faf9e7d,
title = "Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells",
abstract = "Background: About 75-80{\%} of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20{\%} of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Methods: Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. Results: We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. Conclusions: These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.",
keywords = "Aromatase inhibitor, Breast cancer, Drug resistance, Endocrine therapy, Endocrine therapy resistance, Estrogen receptor, HIF, HIF-1 alpha, HIF-1α, Hypoxia, Tamoxifen",
author = "Merc{\`e} Padr{\'o} and Louie, {Raymond J.} and Lananna, {Brian V.} and Adam Krieg and Timmerman, {Luika A.} and Chan, {Denise A.}",
year = "2017",
month = "3",
day = "20",
doi = "10.1186/s12885-017-3140-9",
language = "English (US)",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

AU - Padró, Mercè

AU - Louie, Raymond J.

AU - Lananna, Brian V.

AU - Krieg, Adam

AU - Timmerman, Luika A.

AU - Chan, Denise A.

PY - 2017/3/20

Y1 - 2017/3/20

N2 - Background: About 75-80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Methods: Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. Results: We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. Conclusions: These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.

AB - Background: About 75-80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Methods: Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. Results: We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. Conclusions: These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Drug resistance

KW - Endocrine therapy

KW - Endocrine therapy resistance

KW - Estrogen receptor

KW - HIF

KW - HIF-1 alpha

KW - HIF-1α

KW - Hypoxia

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85015617920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015617920&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3140-9

DO - 10.1186/s12885-017-3140-9

M3 - Article

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 203

ER -